The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

The FDA has approved Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...